经FDA批准并由医生监督

GLP-1 医疗减重计划

多年来一直在为减肥而苦恼吗?
获得医生处方的解决方案,通过调节食欲并解决荷尔蒙和代谢因素,支持可持续减重。

-20.2%

Tirzepatide in SURMOUNT-5 (3)

-13.7%

Semaglutide in SURMOUNT-5 (3)

7 Days

Usual gap from last to first dose (6)

💡

A note on terminology

This page uses tirzepatide and semaglutide, the generic names, rather than brand names, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where each medicine stands in Singapore

Before thinking about a switch, it helps to know what each weekly injection is registered for here.

✓ Semaglutide — Registered for weight management. The 2.4 mg weekly injection is registered for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. (5)

✓ Tirzepatide — Registered for type 2 diabetes. Tirzepatide was first registered to improve blood sugar control in adults with type 2 diabetes. (5)

✓ Tirzepatide — Registered for weight management. It has since been registered for chronic weight management in adults, under similar criteria to semaglutide. (5)

▸ Switching — No official conversion. Neither manufacturer publishes a dose conversion chart between the two, so any switch should be planned by a doctor. (6)

Why the doses don't convert

Semaglutide copies one gut hormone, GLP-1. Tirzepatide acts on two: GLP-1 and GIP, a second hormone that also affects appetite and how the body handles sugar and fat. (1) (2)

The two also come in very different strengths. Semaglutide steps up from 0.25 mg to 2.4 mg a week, while tirzepatide steps up from 2.5 mg to as much as 15 mg a week. (6)

So a milligram of one does not do the same job as a milligram of the other. Conversion tables found online are estimates. A starting dose should be set by a doctor who knows your history.

Fig. 1 — Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both GLP-1 and GIP receptors.
Fig. 1 — Semaglutide acts on one receptor; tirzepatide acts on two.
Fig. 2 — Weekly dose steps: semaglutide 0.25 to 2.4 mg, tirzepatide 2.5 to 15 mg.
Fig. 2 — The weekly dose steps for each medicine.

What the trials found

Each medicine has its own large weight-management trial, shown below. A newer trial, SURMOUNT-5, then compared the two directly. (1) (2) (3)

Trial

Population (n)

Medicine, top dose

Weight change vs placebo

Duration

STEP 1

1,961 · obesity or overweight

Semaglutide 2.4 mg

-14.9% vs -2.4%

68 weeks

SURMOUNT-1

2,539 · obesity or overweight

Tirzepatide 15 mg

-20.9% vs -3.1%

72 weeks

SURMOUNT-5: head to head

In adults with obesity and no diabetes, people on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% on semaglutide. Each person took the highest dose they could tolerate. (3)

Averages hide a wide range

A head-to-head trial in people with type 2 diabetes (SURPASS-2) showed a similar pattern. Even so, some people do very well on semaglutide, and some find tirzepatide harder to tolerate. The right medicine is the one that works for you and suits your other health conditions. (4)

Fig. 3 — SURMOUNT-5 average weight change at week 72: tirzepatide 20.2%, semaglutide 13.7%.
Fig. 3 — Average change in body weight at week 72. Source: SURMOUNT-5 (3).
Common reasons to switch

People move between the two medicines for many reasons, including:

  • Side effects that don't settle
  • Weight loss that has plateaued
  • Another health condition that favours one medicine
  • Supply of particular pen strengths
  • Cost or access
  • Personal preference for the pen or routine

A switch is not a failure. Responses to GLP-1 medicines vary from person to person, and changing treatment is a normal part of finding what works.

Whatever the reason, plan the switch with your doctor. Don't switch on your own with leftover pens or medicine from friends, family or online sellers.

What to expect after switching

Nausea or reflux can return briefly at the start and after each dose increase. Appetite may feel different for a few weeks, and weight loss may pause before settling again. Stopping treatment altogether, rather than switching, usually leads to weight regain. (7) (8) (9)

How a doctor plans the switch

Both medicines are taken once a week. In most cases, the new medicine starts on the day the next dose of the old one would have been due, about seven days after the last injection. The two are never used in the same week. (6)

The starting dose depends on your current dose, how well you tolerated it, how long ago your last injection was, your progress so far and your other medicines. Many doctors start at a lower or middle step rather than the top dose, then adjust.

If several weeks have passed since the last dose, appetite and tolerance may have reset, so the new medicine is usually restarted low.

A review a few weeks after switching lets your doctor check side effects, appetite and weight, and decide whether to move up a step.

Fig. 4 — A typical switch: last dose, about 7 days, first new dose, then a review.
Fig. 4 — A typical switch, from the last dose to the first review.

Tolerability when switching

在整个治疗过程中,医疗监督是必要的,以确保患者的安全和治疗的有效性。

Commonly reported effects

  • Nausea
  • Diarrhoea
  • Constipation
  • Vomiting
  • Reflux or indigestion
  • Injection-site reactions
预约咨询并检查您的资格
减肥有时会让人感到不知所措和充满挑战。然而,您不必独自面对。有了正确的治疗方案和专业的指导,您可以实现可持续的减肥,并自信地重获健康。

立即预约咨询,获取全面的身体分析和个性化治疗方案。
预约咨询
常见问题
参考文献

Studies and sources cited in this document

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
  3. Aronne LJ, Horn DB, le Roux CW, et al., for the SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
  4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products: semaglutide and tirzepatide. Checked November 2026.
  6. Singapore product information for semaglutide 2.4 mg and tirzepatide injections: dosing, dose escalation and missed-dose guidance.
  7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.
  8. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
  9. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325:1414-1425.

Detect any underlying health conditions.

您上次进行全面体检是什么时候?掌控您的健康——从一次 全面全身健康检查 并咨询您的医生。

请说明您目前的问题,或分享任何其他需要在您预约前告知我们的备注。

今天就开始掌控您的健康。

您的提交已收到。
您的提交已收到。我们的客服代表将尽快与您联系!如需更快回复,请致电我们: +65 8129 8877
哎呀!提交表格时出错了。